Evidence map›Paper›PMID 32921269›Full record

ReviewUnited European gastroenterology journal2020

Clinical management of the most common extra-intestinal manifestations in patients with inflammatory bowel disease focused on the joints, skin and eyes.

Fenna M Jansen, Stephan R Vavricka, Alfons A den Broeder, Elke Mgj de Jong, Frank Hoentjen, Willemijn A van Dop

Open access · hybridAbstract readCase ReportsReview
PubMed Full text at PMC Publisher
In one paragraph

Review in United European gastroenterology journal, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed, 2 pooled it
2.9field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 35 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. The Role of IL-23 Inhibitors in Crohn's Disease.Journal of clinical medicine · 2023
    Review
  9. Review
  10. Review
  11. Review
  12. Pediatric uveitis: Role of the pediatrician.Frontiers in pediatrics · 2022
    Review
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 2 countries.

Fenna M JansenDepartment of Medicine, Division of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0001-5454-4335
Stephan R VavrickaDepartment of Medicine, Division of Gastroenterology and Hepatology, University Hospital Zurich, Zurich, Switzerland.
Alfons A den Broeder³Department of Medicine, Division of Rheumatology, Sint Maartenskliniek, Nijmegen, The Netherlands.
Elke Mgj de JongDepartment of Medicine, Division of Dermatology, Radboud University Medical Centre, Nijmegen, The Netherlands.
Frank HoentjenDepartment of Medicine, Division of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.
Willemijn A van DopDepartment of Medicine, Division of Gastroenterology and Hepatology, Radboud University Medical Center, Nijmegen, The Netherlands.ORCID 0000-0002-4653-6594
Radboud University Nijmegen · NLSint Maartenskliniek · NLUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extra-intestinal manifestations (EIMs) of inflammatory bowel disease (IBD) occur frequently and contribute to morbidity and reduced quality of life. The musculoskeletal, ocular and cutaneous organ systems are frequently involved in IBD-related EIMs. By focusing on manifestations involving the joints, skin and eyes, this review will discuss the most common clinically relevant and burdensome EIMs that affect IBD patients, and strives for early recognition, adequate treatment and timely referral. For this purpose, we aimed to create a comprehensive overview on this topic, with the main focus on the treatment of reactive and associated EIMs, including spondyloarthropathies, pyoderma gangrenosum, erythema nodosum, psoriasis and anterior uveitis. The recently developed biologicals enable simultaneous treatment of inflammatory disorders. This review can be used as a helpful guide in daily clinical practice for physicians who are involved in the treatment of IBD patients.

Indexed as

Administration, OralAdministration, TopicalAnti-Inflammatory Agents, Non-SteroidalArthralgiaColitis, UlcerativeCrohn DiseaseDiagnosis, DifferentialErythema NodosumEye DiseasesFemaleHumansMesalamineMiddle AgedPrednisolonePrevalenceTreatment OutcomeAnti-Inflammatory Agents, Non-SteroidalMesalaminePrednisoloneCrohn’s diseasecutaneous manifestationextra-intestinal manifestationInflammatory bowel diseasemusculoskeletal manifestationocular manifestationtherapytreatmentulcerative colitis

Identifiers

PMID32921269
PMCPMC7724540
OpenAlexW3086094186

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.